COVID-19

R&D

Why was R&D productivity up in 2021?

A recent report has found that R&D productivity rose vertiginously during 2021, but how much of this was organic and how much can be attributed to the pandemic?

News

Lilly bags US okay for rival to GSK's COVID-19 drug Xevudy

Eli Lilly has been granted an emergency use authorisation from the FDA for bebtelovimab, its second COVID-19 antibody drug and a rival to GlaxoSmithKline and Vir Biotech's fast-growing Xevu

Digital

Do skills gaps and the COVID brain drain threaten digital tr...

With staff shortages and digital skill gaps being experienced across the spectrum of healthcare, from CROs and pharma to providers, the people-led sector is facing a personnel challenge tha

News

AZ halts development of Beta variant COVID-19 vaccine

AstraZeneca confirmed today that it has discontinued clinical development of a follow-up to its COVID-19 vaccine Vaxzevria targeted at the Beta variant of the virus, which started developme

News

GSK gets £1.4bn sales lift from COVID-19 products in 2021

GlaxoSmithKline's COVID-19 products – antibody drug Xevudy and a vaccine adjuvant – helped drive a 5% increase in 2021 revenues to £34 billion ($46 billion), ahead of what chief executive E

News

Data hackathon analyses truth behind ‘game-changer’ COVID vaccine

Novavax COVID jab 'could save UK money on boosters'

The approval of Novavax' COVID-19 vaccine in Great Britain could help the country save a "considerable amount of money" if it is used in future booster campaigns, according to the former ch

Why was R&D productivity up in 2021?

Lilly bags US okay for rival to GSK's COVID-19 drug Xevudy

Do skills gaps and the COVID brain drain threaten digital tr...

AZ halts development of Beta variant COVID-19 vaccine

GSK gets £1.4bn sales lift from COVID-19 products in 2021

Novavax COVID jab 'could save UK money on boosters'

Iambic prices its IPO, seeking to raise up to $160m

Discover a new era of healthcare panel engagement: Grounded ...

COVID-19

Editor's Picks